AU2022386489A1 - Pharmaceutical composition of glp-1 receptor and gip receptor dual agonist, and use thereof - Google Patents
Pharmaceutical composition of glp-1 receptor and gip receptor dual agonist, and use thereof Download PDFInfo
- Publication number
- AU2022386489A1 AU2022386489A1 AU2022386489A AU2022386489A AU2022386489A1 AU 2022386489 A1 AU2022386489 A1 AU 2022386489A1 AU 2022386489 A AU2022386489 A AU 2022386489A AU 2022386489 A AU2022386489 A AU 2022386489A AU 2022386489 A1 AU2022386489 A1 AU 2022386489A1
- Authority
- AU
- Australia
- Prior art keywords
- pharmaceutical composition
- oeg
- ala
- ile
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Toxicology (AREA)
- Child & Adolescent Psychology (AREA)
- Genetics & Genomics (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111341752 | 2021-11-12 | ||
| CN202111341752.0 | 2021-11-12 | ||
| PCT/CN2022/131375 WO2023083301A1 (zh) | 2021-11-12 | 2022-11-11 | Glp-1受体和gip受体双重激动剂的药物组合物及其用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022386489A1 true AU2022386489A1 (en) | 2024-05-23 |
Family
ID=86335124
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022386489A Pending AU2022386489A1 (en) | 2021-11-12 | 2022-11-11 | Pharmaceutical composition of glp-1 receptor and gip receptor dual agonist, and use thereof |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250115654A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4431522A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024546026A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240109258A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118103391A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022386489A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3237796A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024005663A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202333773A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023083301A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116693652B (zh) * | 2023-08-02 | 2024-01-05 | 北京惠之衡生物科技有限公司 | 一种glp-1/gip受体双重激动剂衍生物及其制备方法和应用 |
| WO2025124473A1 (zh) | 2023-12-12 | 2025-06-19 | 江苏恒瑞医药股份有限公司 | Glp-1类似物治疗代谢疾病的方法及医药用途 |
| WO2025149039A1 (zh) * | 2024-01-12 | 2025-07-17 | 杭州中美华东制药有限公司 | 长效glp-1/gip双激动剂的药物组合物 |
| WO2025252197A1 (zh) * | 2024-06-07 | 2025-12-11 | 江苏恒瑞医药股份有限公司 | 药物组合物 |
| TW202611066A (zh) * | 2024-08-16 | 2026-03-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | Glp-1類似物的醫藥用途 |
| WO2026092429A1 (zh) * | 2024-10-28 | 2026-05-07 | 江苏恒瑞医药股份有限公司 | 药物递送组合物 |
| WO2026153399A1 (zh) * | 2025-01-15 | 2026-07-23 | 江苏恒瑞医药股份有限公司 | 一种药物组合物 |
| WO2026153411A1 (zh) * | 2025-01-20 | 2026-07-23 | 江苏豪森药业集团有限公司 | 一种双重激动剂的药物组合物、制备方法及其医药用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101987868B (zh) * | 2009-07-30 | 2013-09-04 | 江苏豪森医药集团有限公司 | Glp-1类似物的衍生物或其可药用盐和用途 |
| RU2013133803A (ru) * | 2010-12-22 | 2015-01-27 | Маркадиа Байотек, Инк. | Способы лечения метаболических нарушений и ожирения при помощи пептидов на основе глюкагона, активных по отношению к рецепторам гип и гпп |
| KR102002783B1 (ko) * | 2011-06-10 | 2019-07-24 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | 포도당 의존성 인슐리노트로핀 폴리펩타이드 유사물질, 이의 약학적 조성물 및 응용 |
| CA2872314C (en) * | 2012-05-03 | 2021-08-31 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
| HUE035803T2 (en) * | 2012-12-21 | 2018-05-28 | Sanofi Sa | Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists |
| JP7250706B2 (ja) * | 2017-06-21 | 2023-04-03 | アムジエン・インコーポレーテツド | 胃抑制ペプチド受容体(gipr)に対するアンタゴニスト結合タンパク質/glp-1受容体アゴニスト融合タンパク質を使用した代謝障害の治療又は寛解方法 |
| MY206306A (en) * | 2018-10-26 | 2024-12-07 | Novo Nordisk As | Stable semaglutide compositions and uses thereof |
| AU2020256648B2 (en) * | 2019-04-11 | 2026-01-15 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Multi-receptor agonist and medical use thereof |
| WO2021053578A1 (en) * | 2019-09-19 | 2021-03-25 | Dr. Reddy’S Laboratories Limited | Improved purification processes for liraglutide |
| AU2020418207A1 (en) * | 2019-12-30 | 2022-08-25 | Gan & Lee Pharmaceuticals Co., Ltd. | Long-acting GLP-1 compound |
| CN118754965A (zh) * | 2020-05-29 | 2024-10-11 | 北京拓界生物医药科技有限公司 | Glp-1和gip受体双重激动剂化合物及其应用 |
-
2022
- 2022-11-11 CN CN202280069025.XA patent/CN118103391A/zh active Pending
- 2022-11-11 EP EP22892094.8A patent/EP4431522A4/en active Pending
- 2022-11-11 TW TW111143259A patent/TW202333773A/zh unknown
- 2022-11-11 US US18/709,004 patent/US20250115654A1/en active Pending
- 2022-11-11 JP JP2024527503A patent/JP2024546026A/ja active Pending
- 2022-11-11 MX MX2024005663A patent/MX2024005663A/es unknown
- 2022-11-11 CA CA3237796A patent/CA3237796A1/en active Pending
- 2022-11-11 WO PCT/CN2022/131375 patent/WO2023083301A1/zh not_active Ceased
- 2022-11-11 KR KR1020247018683A patent/KR20240109258A/ko active Pending
- 2022-11-11 AU AU2022386489A patent/AU2022386489A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN118103391A (zh) | 2024-05-28 |
| TW202333773A (zh) | 2023-09-01 |
| JP2024546026A (ja) | 2024-12-17 |
| MX2024005663A (es) | 2024-05-28 |
| KR20240109258A (ko) | 2024-07-10 |
| WO2023083301A1 (zh) | 2023-05-19 |
| EP4431522A1 (en) | 2024-09-18 |
| CA3237796A1 (en) | 2023-05-19 |
| EP4431522A4 (en) | 2025-03-26 |
| US20250115654A1 (en) | 2025-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250115654A1 (en) | Pharmaceutical composition of glp-1 receptor and gip receptor dual agonist, and use thereof | |
| US20230190879A1 (en) | Dual-agonist compound for both glp-1 and gip receptors and application thereof | |
| TWI924637B (zh) | 一種多受體激動劑及其醫藥組成物和用途 | |
| US8501693B2 (en) | Use of exendins and exendin agonists and GLP-1 receptor agonists for altering the concentration of fibrinogen | |
| US20260014232A1 (en) | Pharmaceutical Composition of GLP-1 and GIP Receptor Dual Agonist and Use Thereof | |
| US20090209469A1 (en) | Use of Exendins and GLP-1 Receptor Agonists for Altering Lipoprotein Particle Size and Subclass Composition | |
| CN113383014A (zh) | 双受体重激动剂化合物及其药物组合物 | |
| TW202502808A (zh) | Glp-1、gip和gcg受體三激動劑及其應用 | |
| EA053272B1 (ru) | Фармацевтическая композиция двойного агониста рецептора glp-1 и рецептора gip и ее применение | |
| RU2848325C1 (ru) | Соединение с двойной агонистической активностью в отношении рецепторов glp-1 и gip и его применение | |
| RU2816492C2 (ru) | Мультирецепторный агонист и его медицинское применение | |
| HK40069563B (en) | Dual-agonist compound for both glp-1 and gip receptors and application thereof | |
| HK40069563A (en) | Dual-agonist compound for both glp-1 and gip receptors and application thereof | |
| HK40051504A (en) | Dual receptor-acting agonist compounds and pharmaceutical composition thereof | |
| HK40043112A (en) | Multi-receptor agonist and medical use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. Free format text: FORMER APPLICANT(S): FUJIAN SHENGDI PHARMACEUTICAL CO., LTD.; JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. |